106 related articles for article (PubMed ID: 20935688)
1. Visual improvement in established central retinal vein occlusion with long-standing macular edema following systemic eculizumab treatment.
Lockington D; Imrie F; Gillen J; Fitzpatrick A; Willison H
Can J Ophthalmol; 2010 Dec; 45(6):649. PubMed ID: 20935688
[No Abstract] [Full Text] [Related]
2. Differential effects of triamcinolone and bevacizumab in central retinal vein occlusion.
Ehlers JP; Fekrat S
Can J Ophthalmol; 2011 Feb; 46(1):88-9. PubMed ID: 21283167
[No Abstract] [Full Text] [Related]
3. Retinal sensitivity after intravitreal injection of bevacizumab for the treatment of macular edema secondary to retinal vein occlusion.
Yamaike N; Tsujikawa A; Sakamoto A; Ota M; Kotera Y; Miyamoto K; Kita M; Yoshimura N
Retina; 2009 Jun; 29(6):757-67. PubMed ID: 19289982
[TBL] [Abstract][Full Text] [Related]
4. [Bevacizumab and Ranibizumab for macular edema due to retinal vein occlusions].
Niederhauser N; Valmaggia C
Klin Monbl Augenheilkd; 2013 Apr; 230(4):405-8. PubMed ID: 23629792
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
Retina; 2010; 30(7):1002-11. PubMed ID: 20616679
[TBL] [Abstract][Full Text] [Related]
7. Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin(®) ).
Algvere PV; Von Wendt G; Gudmundsson J; Seregard S; Kvanta A
Acta Ophthalmol; 2010 Dec; 88(8):836-41. PubMed ID: 19900206
[TBL] [Abstract][Full Text] [Related]
8. Longer-term outcomes of a prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.
Chang LK; Spaide RF; Klancnik JM; Sorenson J; Slakter JS; Freund KB; Yannuzzi LA; Tseng JJ; Klein R
Retina; 2011 May; 31(5):821-8. PubMed ID: 21317833
[TBL] [Abstract][Full Text] [Related]
9. Comment of article by Matsumoto Y.
Campa C; D'Angelo S; Incorvaia C
Retina; 2008 May; 28(5):782; author reply 782-3. PubMed ID: 18463528
[No Abstract] [Full Text] [Related]
10. Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion.
Parveen S; Narayanan R; Sambhav K; Bhatia K
Retina; 2010 Sep; 30(8):1324-5; author reply 1325. PubMed ID: 20827152
[No Abstract] [Full Text] [Related]
11. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion.
Cekiç O; Cakır M; Yazıcı AT; Alagöz N; Bozkurt E; Faruk Yılmaz O
Curr Eye Res; 2010 Oct; 35(10):925-9. PubMed ID: 20858114
[TBL] [Abstract][Full Text] [Related]
12. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials.
Thach AB; Yau L; Hoang C; Tuomi L
Ophthalmology; 2014 May; 121(5):1059-66. PubMed ID: 24424249
[TBL] [Abstract][Full Text] [Related]
13. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.
Mayer WJ; Remy M; Wolf A; Kook D; Kampik A; Ulbig M; Reznicek L; Haritoglou C
Ophthalmologica; 2012; 228(2):110-6. PubMed ID: 22739239
[TBL] [Abstract][Full Text] [Related]
14. Area of peripheral retinal nonperfusion and treatment response in branch and central retinal vein occlusion.
Singer M; Tan CS; Bell D; Sadda SR
Retina; 2014 Sep; 34(9):1736-42. PubMed ID: 24732695
[TBL] [Abstract][Full Text] [Related]
15. Treatment of branch retinal vein occlusion induced macular edema with bevacizumab.
Abegg M; Tappeiner C; Wolf-Schnurrbusch U; Barthelmes D; Wolf S; Fleischhauer J
BMC Ophthalmol; 2008 Sep; 8():18. PubMed ID: 18823536
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial.
Priglinger SG; Wolf AH; Kreutzer TC; Kook D; Hofer A; Strauss RW; Alge CS; Kunze C; Haritoglou C; Kampik A
Retina; 2007 Oct; 27(8):1004-12. PubMed ID: 18040236
[TBL] [Abstract][Full Text] [Related]
17. Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion.
Rensch F; Jonas JB; Spandau UH
Acta Ophthalmol; 2009 Feb; 87(1):77-81. PubMed ID: 18937800
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion:results after 12 months and multiple regression analysis.
Kondo M; Kondo N; Ito Y; Kachi S; Kikuchi M; Yasuma TR; Ota I; Kensaku M; Terasaki H
Retina; 2009 Oct; 29(9):1242-8. PubMed ID: 19672216
[TBL] [Abstract][Full Text] [Related]
19. Results of bevacizumab as the primary treatment for retinal vein occlusions.
Figueroa MS; Contreras I; Noval S; Arruabarrena C
Br J Ophthalmol; 2010 Aug; 94(8):1052-6. PubMed ID: 20679089
[TBL] [Abstract][Full Text] [Related]
20. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion.
Pai SA; Shetty R; Vijayan PB; Venkatasubramaniam G; Yadav NK; Shetty BK; Babu RB; Narayana KM
Am J Ophthalmol; 2007 Apr; 143(4):601-6. PubMed ID: 17306753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]